NYSE
$10.01▲ 0.50%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $39.7MShares out 4.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 4d agoRegular26.10.21 02:184Ownership#●●●#●●●
EAGLE CAPITAL GROWTH FUND, INC.
Insider David C. Sims of EAGLE CAPITAL GROWTH FUND, INC. filed a Form 4 on October 20, 2026, reporting a change in beneficial ownership of securities as of October 16, 2026. This filing serves as the official record of the insider's equity transaction.…more
$10.01+0.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.3After-hours26.09.04 05:414Ownership
EAGLE CAPITAL GROWTH FUND, INC.
Insider Luke E. Sims of EAGLE CAPITAL GROWTH FUND, INC. filed a Form 4 on September 3, 2026, reporting changes in beneficial ownership as of September 1, 2026. This filing serves as an official notification to the SEC regarding the insider's equity position.…more
$10.01+0.50%vs prev closeView filingShare - 8.20After-hours26.08.21 06:05N-CSRSOther
EAGLE CAPITAL GROWTH FUND, INC.
Eagle Capital Growth Fund's net asset value (NAV) rose 2% in the first half of 2026, underperforming the S&P 500's 10% return. As of June 30, 2026, total net assets reached $48,326,254, with a NAV per share of $12.18. The fund managers added Progressive Corporation to the portfolio, maintaining their commitment to value investing.…more
$10.01+0.50%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.10Pre-market26.08.10 20:00Bullish#●●●#●●●
그리폴스, 알파-1 항트립신 결핍증 치료제 임상 3상 완료
그리폴스가 폐기종 치료제인 '프로라스틴-C'의 임상 3상 시험을 성공적으로 마쳤습니다. 이번 임상 완료는 향후 신약 승인 및 시장 확대 가능성을 높이는 긍정적인 신호로 평가됩니다.…more
$10.01+0.50%vs prev close